Milestone Pharmaceuticals Stock Performance
| MIST Stock | USD 1.88 0.17 8.29% |
The company secures a Beta (Market Risk) of 1.02, which conveys a somewhat significant risk relative to the market. Milestone Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Milestone Pharmaceuticals is expected to follow. Milestone Pharmaceuticals right now secures a risk of 5.44%. Please verify Milestone Pharmaceuticals maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if Milestone Pharmaceuticals will be following its current price movements.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Milestone Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Milestone Pharmaceuticals is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
1 | MIST Stock Hits 52-Week High at 2.42 Amid Positive Momentum - Investing.com | 12/31/2024 |
2 | Acquisition by Fischer Seth H. Z. of 42000 shares of Milestone Pharmaceuticals at 3.45 subject to Rule 16b-3 | 01/24/2025 |
3 | Acquisition by Oliveto Joseph of 266400 shares of Milestone Pharmaceuticals subject to Rule 16b-3 | 01/27/2025 |
4 | Conduits AI-Powered Drug Development Takes Major Leap Real-Time Trial Dashboard Unveiled - StockTitan | 02/07/2025 |
5 | Retail investors who hold 57 percent of Milestone Pharmaceuticals Inc. gained 14, institutions profited as well | 02/11/2025 |
6 | Short Interest in Milestone Pharmaceuticals Inc. Declines By 27.9 | 02/14/2025 |
7 | Milestone Pharmaceuticals Prepares for CARDAMYST Launch - TipRanks | 02/25/2025 |
8 | DONNA KARAN CASHMERE MIST INTRODUCES A NEW CHAPTER FOR SPRING 2025, FEATURING IMAAN HAMMAM IN A CAPTIVATING CAMPAIGN | 02/28/2025 |
9 | Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 03/04/2025 |
10 | Milestone Pharmaceuticals Q4 Earnings Snapshot | 03/13/2025 |
11 | Acquisition by Liebert Debra K. of 30000 shares of Milestone Pharmaceuticals at 6.07 subject to Rule 16b-3 | 03/14/2025 |
12 | Milestone Pharmaceuticals Earns Buy Rating from HC Wainwright | 03/17/2025 |
13 | Acquisition by Lorenz Muller of 200000 shares of Milestone Pharmaceuticals at 6.26 subject to Rule 16b-3 | 03/20/2025 |
14 | Acquisition by Liebert Debra K. of 4000 shares of Milestone Pharmaceuticals at 5.26 subject to Rule 16b-3 | 03/21/2025 |
| Begin Period Cash Flow | 13.8 M |
Milestone |
Milestone Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 198.00 in Milestone Pharmaceuticals on December 26, 2024 and sell it today you would lose (10.00) from holding Milestone Pharmaceuticals or give up 5.05% of portfolio value over 90 days. Milestone Pharmaceuticals is currently generating 0.0573% in daily expected returns and assumes 5.4447% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Milestone, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Milestone Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Milestone Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Milestone Pharmaceuticals, and traders can use it to determine the average amount a Milestone Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0105
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | MIST | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.44 actual daily | 48 52% of assets are more volatile |
Expected Return
| 0.06 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Milestone Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Milestone Pharmaceuticals by adding Milestone Pharmaceuticals to a well-diversified portfolio.
Milestone Pharmaceuticals Fundamentals Growth
Milestone Stock prices reflect investors' perceptions of the future prospects and financial health of Milestone Pharmaceuticals, and Milestone Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Milestone Stock performance.
| Return On Equity | -2.78 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 94.48 M | ||||
| Shares Outstanding | 53.35 M | ||||
| Price To Earning | (4.44) X | ||||
| Price To Book | 8.32 X | ||||
| Price To Sales | 77.32 X | ||||
| EBITDA | (42.1 M) | ||||
| Net Income | (41.52 M) | ||||
| Cash And Equivalents | 86.24 M | ||||
| Cash Per Share | 2.87 X | ||||
| Total Debt | 54.8 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.26 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (28.85 M) | ||||
| Earnings Per Share | (0.67) X | ||||
| Market Capitalization | 109.38 M | ||||
| Total Asset | 75.5 M | ||||
| Retained Earnings | (367.55 M) | ||||
| Working Capital | 65.8 M | ||||
| Current Asset | 110.42 M | ||||
| Current Liabilities | 7.17 M | ||||
About Milestone Pharmaceuticals Performance
Assessing Milestone Pharmaceuticals' fundamental ratios provides investors with valuable insights into Milestone Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Milestone Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (226.53) | (237.85) | |
| Return On Tangible Assets | (0.91) | (0.96) | |
| Return On Capital Employed | (0.62) | (0.66) | |
| Return On Assets | (0.91) | (0.96) | |
| Return On Equity | (4.09) | (3.89) |
Things to note about Milestone Pharmaceuticals performance evaluation
Checking the ongoing alerts about Milestone Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Milestone Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Milestone Pharmaceuticals had very high historical volatility over the last 90 days | |
| Milestone Pharmaceuticals may become a speculative penny stock | |
| Milestone Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (41.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Milestone Pharmaceuticals currently holds about 86.24 M in cash with (28.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Milestone Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Acquisition by Lorenz Muller of 200000 shares of Milestone Pharmaceuticals at 6.26 subject to Rule 16b-3 |
- Analyzing Milestone Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Milestone Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Milestone Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Milestone Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Milestone Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Milestone Pharmaceuticals' stock. These opinions can provide insight into Milestone Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.